Small Molecules & TPD World Series
The Small Molecules and TPD World Series is committed to delivering the most comprehensive collection of industry-dedicated forums, exclusively focusing on the specific challenges faced for each community of small molecules and protein degradation drug developers.
The goal for this event series is to provide your team with the platform to connect, learn and fast-track first-in-class or next generation of selective, orally bioavailable and clinically efficacious small molecules for undrugged or hard-to-drug targets to meet the needs of patients globally.
View the Small Molecules & TPD World Series conference calendar below. If you have any questions, get in touch at info@hansonwade.com.
Download the partnership prospectus to access key event information, audience breakdown, testimonials and partnership opportunities.
Delivering & Translating Degraders of Extracellular & Intracellular CNS Proteins
January 16-18, 2024 | Boston, MA
Accelerate the Discovery, Validation and Clinical Translation of Novel and Rationally Designed Molecular Glues through Systematic Screening, Expanding Ligase Toolbox and Optimizing Pharmacological Properties
January 30 - February 1, 2024 | Boston, MA
Harnessing the Power of Advanced Computing, Genomic & Structure-Based Technologies to Safely & Selectively Target GPCRs with Next Generation Small Molecules & Biologics in Oncology, Metabolic Disorders & Beyond
March 5-7, 2024 | Boston, MA
Expanding the Druggable Landscape Whilst Achieving Clinical Proof-of-Concept & Approvals with Novel PROTACs, Glues & TACs to Successfully Drug High Value Intra- & Extra-Cellular Targets
March 19-21, 2024 | London, UK
Uncovering Unexploited Ligases & Utilizing New Ligand Screening Technologies to Mediate Degradation
April 14-16, 2024 | Boston, MA
Accelerate Hit Discovery, Predict PPI Interactions and Gain High-Throughput Proof of Concept to Target Clinically Relevant "Hard-to-Drug" Proteins
July 23-25, 2024 | Boston, MA
Advancing the Development, from Research to Market, of Effective Therapies for RAS-Mutant Cancers Ranging from G12C to Q61 Modalities to Attain Targeted Drugs for Patients in Need
September 3-5, 2024 | Boston, MA
Improve Selectivity, Reduce Toxicity & Overcome Limitations of Preclinical Models & Clinical Biomarkers to Accelerate Translation & Development of Hippo Pathway Targeted Therapeutics for Patients
October 29-31, 2024 | Boston, MA
Spearheading Degrader Therapeutics Towards the First Approval
October 29-November 1, 2024 | Boston, MA
Developing Reproducible, High-Throughput & Cost-Effective Assays & Screens to Identify Novel E3 Ligases & Disease-Causing Proteins to Accelerate PROTAC, Molecular Glue & Next-Generation Degrader R&D
December 3-5, 2024 | San Diego, CA
Accelerating Screening & Discovery of Potent Covalent Inhibitors & Degraders with Improved Triaging, Selectivity & Safety for Targeting Hard-to-Drug Targets
December 10-12, 2024 | Boston, MA
Improve Rational Design, Specificity & Selectivity of Direct & Indirect RNA Binders to Reduce Toxicity in Preclinical Models & Enable Robust Translation into the Clinic
December 10-12, 2024 | Boston, MA